Literature DB >> 2220728

Liver pathology in morbidly obese patients with and without diabetes.

J F Silverman1, K F O'Brien, S Long, N Leggett, P G Khazanie, W J Pories, H T Norris, J F Caro.   

Abstract

The contribution of obesity and/or diabetes to liver pathology in the morbidly obese patient is controversial. We studied the liver biopsies of 100 consecutive patients undergoing gastric bypass surgery for morbid obesity. Multiple morphologic parameters were analyzed and graded independently, without knowledge of the clinical history, liver function tests, and oral glucose tolerance results of the patients. Six percent of the entire group demonstrated no fat, 42% mild fat, 20% moderate fat, and 24% severe fatty metamorphosis of the liver. Twenty-three percent of the patients had central vein fibrosis, 23% sinusoidal fibrosis, 19% bridging fibrosis, and 4% cirrhosis. Thirty-six percent of the patients had some degree of steatohepatitis, 66% possessed so-called glycogen nuclei of hepatocytes, 6% had PAS-positive thickening of blood vessels in the portal tracts, and 1% had lipogranulomas. The degree of fatty metamorphosis and fibrosis was analyzed in three separate groups, categorized by the glycemic status of the patient: 46 patients with normal glucose tolerance (NGT), 23 patients with impaired glucose tolerance (IGT), and 31 patients with non-insulin-dependent diabetes mellitus (NIDDM). Increasing severity of fatty metamorphosis from the normoglycemic obese to the diabetic obese patients was found, which was statistically significant by chi 2 analysis. Four of the six patients showing no fatty metamorphosis were normoglycemic. Glycogen nuclei and PAS-positive blood vessels were significantly more prevalent in the diabetic obese than in the normal obese. In conclusion, the distribution of significant liver histopathology in the morbidly obese patient correlates in severity with the degree of impaired glycemic status.

Entities:  

Mesh:

Year:  1990        PMID: 2220728

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  61 in total

1.  Simultaneous changes in high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis and those underlying molecular mechanisms in novel SHRSP5/Dmcr rat.

Authors:  Takashi Moriya; Kazuya Kitamori; Hisao Naito; Yukie Yanagiba; Yuki Ito; Nozomi Yamagishi; Hazuki Tamada; Xiaofang Jia; Satoru Tsuchikura; Katsumi Ikeda; Yukio Yamori; Tamie Nakajima
Journal:  Environ Health Prev Med       Date:  2012-03-11       Impact factor: 3.674

2.  Hepatitis C virus does not cause nonalcoholic steatohepatitis.

Authors:  D W Rogers; C H Lee; D C Pound; S Kumar; O W Cummings; L Lumeng
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

3.  Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.

Authors:  Michael Charlton; Anuradha Krishnan; Kimberly Viker; Schuyler Sanderson; Sophie Cazanave; Andrea McConico; Howard Masuoko; Gregory Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

Review 4.  Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Melanie D Beaton
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

Review 5.  Nonalcoholic fatty liver disease: a clinical review.

Authors:  David A Sass; Parke Chang; Kapil B Chopra
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

6.  Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.

Authors:  Savino Bruno; Patrick Maisonneuve; Paola Castellana; Nicole Rotmensz; Sonia Rossi; Marco Maggioni; Marcello Persico; Alberto Colombo; Franco Monasterolo; Donata Casadei-Giunchi; Franco Desiderio; Tommaso Stroffolini; Virgilio Sacchini; Andrea Decensi; Umberto Veronesi
Journal:  BMJ       Date:  2005-03-03

7.  Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity.

Authors:  Phui-Ly Liew; Wei-Jei Lee; Weu Wang; Yi-Chih Lee; Wei-Yu Chen; Chia-Lang Fang; Ming-Te Huang
Journal:  Obes Surg       Date:  2008-05-06       Impact factor: 4.129

Review 8.  Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders.

Authors:  William S Blaner
Journal:  Pharmacol Ther       Date:  2019-01-29       Impact factor: 12.310

Review 9.  The metabolic syndrome and nonalcoholic fatty liver disease in children.

Authors:  Shikha S Sundaram; Phil Zeitler; Kristen Nadeau
Journal:  Curr Opin Pediatr       Date:  2009-08       Impact factor: 2.856

10.  Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis.

Authors:  A Nonomura; Y Mizukami; M Unoura; K Kobayashi; Y Takeda; R Takeda
Journal:  Gastroenterol Jpn       Date:  1992-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.